Tomorrow Investor

Draganfly Announces Pricing of US$50.0 Million Registered Direct Offering

Draganfly Secures US$50 Million in Registered Direct Offering | GlobeNewsWire

Saskatoon, SK., Feb. 25, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the pricing of a registered direct offering to purchase 7,150,000 common shares (or pre-funded warrants in lieu thereof) of the Company (each, a “Common Share” or “Pre-Funded Warrant”), at a price of US$7.00, for gross proceeds of approximately US$50.0 million, before deducting placement agent discounts and offering expenses (the “Offering”).

This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.

Brief Summary

Draganfly Inc., a leader in drone technology, is thrilled to announce its recent registered direct offering, looking to raise $50 million through the sale of 7,150,000 common shares priced at $7.00 each. This strategic move positions the company to enhance its technological advancements and expand its operations.

  • Offering Size: Directed registered offering of 7,150,000 shares
  • Price per Share: $7.00
  • Total Proceeds: Approximately $50 million
  • Use of Proceeds: Expansion of drone technology and operations

Why it matters: This funding marks a significant milestone for Draganfly, signaling confidence in its growth strategy and ongoing innovation in the drone solutions sector.

Read the Full Article

This is a summary of the press release. For the complete article and any additional details, please visit the original source.

Read Full Article

Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.

Tomorrow Investor
The Tomorrow Investor

Markets research for retail investors

Independent coverage of small-cap equities, biotech catalysts, and emerging market opportunities.